CDKN1A and breast carcinoma: In the breast cancer group, high (3+), low (1+), and moderate (2+) signals for p21 IHC reactions were expressed in 56.67%, 23.33%, and 13.33% of the samples, respectively, while there was no signal in 6.67% of the samples.